Glaukos Soars 26% on “Exceptional” Quarter and $1 Billion 2027 Sales Outlook
Glaukos (GKOS) stock rose 26% after reporting record Q3 sales of $211.0M, up 58% YoY, and raising 2026 sales guidance to $775-785M. The company also provided preliminary 2027 sales guidance of $1B. iDose TR and Epioxa contributed 61% of sales. Glaukos trades at 647x forward earnings. Analysts and competitors Alcon (ALC) and AbbVie (ABBV) are watching closely.
How this was made
The 30-second read
Why it matters
The article frames the catalyst as record Q3 sales, raised 2026 guidance, and a preliminary 2027 sales target of $1B, alongside a move to operating profit.
Market read
Traders can reassess near-term expectations and valuation risk after the company’s fresh guidance and operating-profit inflection.
What to watch
Medicare contractor proposed coverage rules for iDose TR and the “highly preliminary” nature of the 2027 figure may increase uncertainty around timing and durability of demand.
Background
Glaukos is a glaucoma-focused medical device and therapeutics company, with iDose TR and Epioxa driving recent growth.
Ticker impact
Glaukos reported record Q3 sales and raised 2026 guidance to $775-$785M, plus preliminary 2027 sales guidance of $1B.
Likely further upside pressure in the near term as traders price in the 2027 $1B target, tempered by concerns about execution and coverage decisions.
The article cites fresh, company-specific guidance numbers and a same-day +26% move, indicating the market is reacting to new fundamentals rather than commentary.
Market effects
Competitive read-through for glaucoma implant and eye-care peers as Glaukos gains share signals potential demand shift.
US-listed medtech sentiment, with potential spillover to US ophthalmology/biopharma names ahead of their own upcoming reports.
Limited beyond US peers, but could influence global investor positioning in ophthalmology device companies.
Counterpoint
The stock trades at hundreds of times forward earnings, so any delay in converting the $1B 2027 sales target into earnings, or adverse coverage outcomes, could trigger sharp mean reversion.
Key entities
- companyGlaukos
Reported record Q3 sales, raised 2026 guidance, and issued preliminary 2027 sales outlook.
- productiDose TR
Glaucoma implant whose sales growth is central to reaching the 2027 $1B target.
- productEpioxa
Keratoconus treatment launched in March, contributing to the sales mix.
- companyAlcon
Peer cited as competing in glaucoma implantables; expected to report soon.
- companyAbbVie
Peer cited for glaucoma drops; expected to report soon.
